

产品名称: ANA-12

产品别名: ANA-12

生物活性:																													
Description	ANA-12 is a potent and selective TrkB antagonist with IC ₅₀ s of 45.6 nM and 41.1 μM for the high and low affinity sites, respectively.																												
In Vitro	ANA-12 (10 nM) prevents BDNF-induced neurite outgrowth in the TrkB-expressing cells, and completely abolishes the effects of BDNF at concentrations up to 10-100 μM[1].																												
In Vivo	ANA-12 (0.5 mg/kg, i.p.) partially inhibits the total endogenous TrkB activity in the whole brain of mice. ANA-12, injected in mice, demonstrates anxiolytic and antidepressive activities at 0.5 mg/kg. ANA-12 (0.5, 1.0, and 2.0 mg/kg) does not affect neuron survival[1]. ANA-12 (0.5 mg/kg) shows antidepressant effects in lipopolysaccharide (LPS)-induced depression-like behavior. ANA-12 (0.5 mg/kg) significantly attenuates an increased immobility time in depressed mice. In the TST, FST, and SPT, ANA-12 (0.5 mg/kg) does not show antidepressant-like effects in the control mice[2]. ANA-12 (0.5 mg/kg, i.p.) reverses the diminished self-administration of cocaine in CocSired rats[3].																												
Solvent&Solubility	In Vitro: DMSO : 9.09 mg/mL (22.31 mM; Need ultrasonic) H ₂ O : < 0.1 mg/mL (insoluble)																												
	<table border="1"><thead><tr><th rowspan="2">Preparing Stock Solutions</th><th>Solvent</th><th>Mass</th><th>Concentration</th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr></thead><tbody><tr><td>1 mM</td><td>2.4540 mL</td><td></td><td>12.2702 mL</td><td>24.5405 mL</td><td></td></tr><tr><td>5 mM</td><td>0.4908 mL</td><td></td><td>2.4540 mL</td><td>4.9081 mL</td><td></td></tr><tr><td>10 mM</td><td>0.2454 mL</td><td></td><td>1.2270 mL</td><td>2.4540 mL</td><td></td></tr></tbody></table>					Preparing Stock Solutions	Solvent	Mass	Concentration	1 mg	5 mg	10 mg	1 mM	2.4540 mL		12.2702 mL	24.5405 mL		5 mM	0.4908 mL		2.4540 mL	4.9081 mL		10 mM	0.2454 mL		1.2270 mL	2.4540 mL
Preparing Stock Solutions	Solvent	Mass	Concentration	1 mg	5 mg		10 mg																						
	1 mM	2.4540 mL		12.2702 mL	24.5405 mL																								
5 mM	0.4908 mL		2.4540 mL	4.9081 mL																									
10 mM	0.2454 mL		1.2270 mL	2.4540 mL																									
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。 -80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。																													
In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1.请依序添加每种溶剂： 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline Solubility: 1.43 mg/mL (3.51 mM); Suspended solution; Need ultrasonic 此方案可获得 1.43 mg/mL (3.51 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例，取 100 μL 14.299999 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入 50 μL Tween-80，混合均匀；然后继续加入 450 μL 生理盐水定容至 1 mL 2.请依序添加每种溶剂： 10% DMSO → 90% corn oil Solubility: ≥ 1.43 mg/mL (3.51 mM); Clear solution 此方案可获得 ≥ 1.43 mg/mL (3.51 mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 14.299999 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均																													

	<p>匀。</p> <p>3. 请依序添加每种溶剂: 5% DMSO → 40% PEG300 → 5% Tween-80 → 50% saline Solubility: 1 mg/mL (2.45 mM); Suspended solution; Need ultrasonic</p> <p>4. 请依序添加每种溶剂: 5% DMSO → 95% (20% SBE-β-CD in saline) Solubility: ≥ 0.45 mg/mL (1.10 mM); Clear solution</p> <p>5. 请依序添加每种溶剂: 5% DMSO → 95% corn oil Solubility: ≥ 0.45 mg/mL (1.10 mM); Clear solution</p>
References	<p>[1]. Cazorla M, et al. Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. <i>J Clin Invest.</i> 2011 May;121(5):1846-57.</p> <p>[2]. Fang X, et al. Brain-derived neurotrophic factor-TrkB signaling in the medial prefrontal cortex plays a role in the anhedonia-like phenotype after spared nerve injury. <i>Eur Arch Psychiatry Clin Neurosci.</i> 2018 Jun 7.</p> <p>[3]. Zhang JC, et al. Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression. <i>Psychopharmacology (Berl).</i> 2015 Dec;232(23):4325-35.</p> <p>[4]. Vassoler FM, et al. Epigenetic inheritance of a cocaine-resistance phenotype. <i>Nat Neurosci.</i> 2013 Jan;16(1):42-7.</p>

实验参考:

Animal Administration	On the day of injection, ketamine (ketamine hydrochloride, 10 mg/kg), 7,8-dihydroxyflavone (7,8-DHF; 10 mg/kg), and ANA-12, N2-(2-[(2-oxoazepan-3-yl)amino]carbonyl)phenyl)benzo[b]thiophene-2-carboxamide (0.5 mg/kg) are prepared in vehicle of 17 % dimethyl sulfoxide (DMSO) in phosphate-buffered saline. The doses of ketamine (10 mg/kg), 7,8-DHF (10 mg/kg), and ANA-12 (0.5 mg/kg) are selected. All compounds are administered intraperitoneally (i.p.) to mice. [2]
References	<p>[1]. Cazorla M, et al. Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. <i>J Clin Invest.</i> 2011 May;121(5):1846-57.</p> <p>[2]. Fang X, et al. Brain-derived neurotrophic factor-TrkB signaling in the medial prefrontal cortex plays a role in the anhedonia-like phenotype after spared nerve injury. <i>Eur Arch Psychiatry Clin Neurosci.</i> 2018 Jun 7.</p> <p>[3]. Zhang JC, et al. Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression. <i>Psychopharmacology (Berl).</i> 2015 Dec;232(23):4325-35.</p> <p>[4]. Vassoler FM, et al. Epigenetic inheritance of a cocaine-resistance phenotype. <i>Nat Neurosci.</i> 2013 Jan;16(1):42-7.</p>